Ferring Ventures Limited

Quick facts

Phase 3 pipeline

• Celecoxib Oral Product · Rheumatology / Pain Management
  Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain.
• rAd-IFN · Oncology
  rAd-IFN is a recombinant adenovirus vector-based gene therapy that expresses interferon-alpha.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ferring Ventures Limited portfolio CI brief
• Ferring Ventures Limited pipeline updates RSS